Search results
Results from the WOW.Com Content Network
A synapse during re-uptake. Note that some neurotransmitters are lost and not reabsorbed. Reuptake is the reabsorption of a neurotransmitter by a neurotransmitter transporter located along the plasma membrane of an axon terminal (i.e., the pre-synaptic neuron at a synapse) or glial cell after it has performed its function of transmitting a neural impulse.
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant. Reuptake inhibitors ( RIs ) are a type of reuptake modulators . It is a drug that inhibits the plasmalemmal transporter -mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron .
Such neurotransporter cotransport systems are highly diverse, as recent development indicates that uptake systems are generally selective and associate with a specific neurotransmitter. [4] Normally, transporters in the synaptic membrane serve to remove neurotransmitters from the synaptic cleft and prevent their action or bring it to an end.
This bidirectional communication between astrocytes and neurons add complexity to brain signaling, with implications for brain function and neurological disorders. [10] [11] Enzyme degradation – proteins called enzymes break the neurotransmitters down. Reuptake – neurotransmitters are
EAAT2 is responsible for over 90% of glutamate reuptake within the central nervous system (CNS). [7] [12] The EAAT3-4 subtypes are exclusively neuronal, and are expressed in axon terminals, [8] cell bodies, and dendrites. [9] [15] Finally, EAAT5 is only found in the retina where it is principally localized to photoreceptors and bipolar neurons ...
In a 2023 study a possible connection between SSRI usage and the onset of mitral valve regurgitation was identified, indicating that SSRIs could hasten the progression of degenerative mitral valve regurgitation (DMR), especially in individuals carrying 5-HTTLPR genotype. The study's authors suggest that genotyping should be performed on people ...
Niaprazine (Nopron) – a drug related to this group but does not inhibit the reuptake of serotonin or the other monoamines. Medifoxamine (Clédial, Gerdaxyl) – could perhaps technically be said to belong to this group, as it is a serotonin–dopamine reuptake inhibitor and 5-HT 2A and 5-HT 2C receptor antagonist, but not grouped as such. [1]